Ola Weiland
Overview
Explore the profile of Ola Weiland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westin J, Ydreborg M, Kampmann C, Wejstal R, Weiland O
Infect Dis (Lond)
. 2023 Aug;
55(11):786-793.
PMID: 37561507
Background: Effective direct-acting antiviral treatment against hepatitis C virus infection is available in many countries worldwide. Despite good treatment results, a proportion of patients does not respond to treatment. The...
2.
Lindgren P, Lofvendahl S, Bradvik G, Weiland O, Jonsson B
Eur J Health Econ
. 2021 Dec;
23(6):1059-1070.
PMID: 34855072
Background: In 2015, the Swedish government in an unprecedented move decided to allocate 150 million € to provide funding for new drugs for hepatitis C. This was triggered by the...
3.
Waldenstrom J, Kaberg M, Alanko Blome M, Widell A, Bjorkman P, Nilsson S, et al.
Scand J Gastroenterol
. 2021 May;
56(7):855-861.
PMID: 34034600
Objectives: Absence of a functional interferon-λ 4 (IFN-λ4) gene () predicts spontaneous resolution of acute hepatitis C virus (HCV) infections in regions with a predominance of genotype 1, whereas variants...
4.
Mejer N, Fahnoe U, Galli A, Ramirez S, Weiland O, Benfield T, et al.
Antimicrob Agents Chemother
. 2020 Sep;
64(12).
PMID: 32928732
Ribavirin has been used for 25 years to treat patients with chronic hepatitis C virus (HCV) infection; however, its antiviral mechanism of action remains unclear. Here, we studied virus evolution...
5.
Lindgren P, Lofvendahl S, Bradvik G, Weiland O
J Viral Hepat
. 2020 Sep;
28(1):142-146.
PMID: 32896927
The cost-effectiveness of the second-generation direct-acting antivirals (DAA) has received considerable attention; however, their effect on wider societal costs has remained relatively unexplored. The aim of this study was to...
6.
Kamal H, Weiland O, Aleman S
Hepatology
. 2020 Aug;
74(2):1127-1128.
PMID: 32767793
No abstract available.
7.
Kaberg M, Larsson S, Jerkeman A, Nystedt A, Duberg A, Kovamees J, et al.
Scand J Gastroenterol
. 2020 May;
55(5):574-580.
PMID: 32356496
Hepatitis C virus (HCV) is a slowly progressive disease, often transmitted among people who inject drugs (PWID). Mortality in PWID is high, with an overrepresentation of drug-related causes. This study...
8.
Kamal H, Westman G, Falconer K, Duberg A, Weiland O, Haverinen S, et al.
Hepatology
. 2020 Mar;
72(4):1177-1190.
PMID: 32145073
Background And Aims: Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have, however, been mainly from tertiary care centers, with...
9.
Kaberg M, Weiland O
Liver Int
. 2020 Feb;
40 Suppl 1:61-66.
PMID: 32077600
In 2016 the WHO set a goal to obtain an 80% reduction in new chronic HCV cases, requiring a level of diagnosis of 90%, treatment coverage of 80% and resulting...
10.
Kaberg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekstrom A, et al.
Infect Dis (Lond)
. 2020 Feb;
52(5):336-346.
PMID: 32072841
Sharing of unsterile injection equipment contributes to transmission of hepatitis C virus (HCV), HIV and hepatitis B virus (HBV) among people who inject drugs (PWID) but is largely preventable through...